A Study of OsrHSA in Adult Healthy Male and Female Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

November 4, 2019

Primary Completion Date

March 17, 2020

Study Completion Date

July 13, 2020

Conditions
Ascites Hepatic
Interventions
DRUG

OsrHSA 20 mg/kg IV

A single dose of OsrHSA 20 mg/kg IV infusion at a rate lower than 2 ml/min

DRUG

OsrHSA 40 mg/kg IV

A single dose of OsrHSA 40 mg/kg IV infusion at a rate lower than 2 ml/min

DRUG

OsrHSA 80 mg/kg IV

A single dose of OsrHSA 80 mg/kg IV infusion at a rate lower than 2 ml/min

DRUG

OsrHSA 140 mg/kg IV

A single dose of OsrHSA 140 mg/kg IV infusion at a rate lower than 2 ml/min

DRUG

OsrHSA 200 mg/kg IV

A single dose of OsrHSA 200 mg/kg IV infusion at a rate lower than 2 ml/min

OTHER

Placebo

Normal Saline (0.9% Sodium Chloride)

Trial Locations (1)

90630

WCCT Global, Inc, Cypress

Sponsors
All Listed Sponsors
lead

Healthgen Biotechnology Corp.

INDUSTRY

NCT04384523 - A Study of OsrHSA in Adult Healthy Male and Female Volunteers | Biotech Hunter | Biotech Hunter